Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Core Insights - Vaxcyte, Inc. will report its financial results for Q4 and full year 2024 on February 25, 2025, followed by a conference call and webcast to discuss the results and provide a business update [1] Company Overview - Vaxcyte is a clinical-stage vaccine innovation company focused on engineering high-fidelity vaccines to combat bacterial diseases [3] - The company is developing broad-spectrum conjugate and novel protein vaccines, including VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, and VAX-24, a 24-valent PCV candidate [3] - VAX-31 is advancing to a Phase 3 adult clinical program and is currently in a Phase 2 infant clinical program, aimed at preventing invasive pneumococcal disease in both adults and infants [3] - VAX-24 is designed to cover more serotypes than any infant PCV currently on the market and is also in a Phase 2 infant study [3] Technology and Innovation - Vaxcyte utilizes modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, to produce complex vaccines [4] - The company's approach aims to accelerate the creation and delivery of high-fidelity vaccines with enhanced immunological benefits [4] Additional Pipeline Candidates - Vaxcyte's pipeline includes VAX-A1, a prophylactic vaccine for Group A Strep infections; VAX-PG, a therapeutic vaccine for periodontal disease; and VAX-GI, a vaccine candidate for Shigella [4]